NanGenex Announce Global Launch of NanoActive
News Sep 09, 2009
NanGenex Inc. (formerly known as ComErgen) announced the global launch of its NanoActive. “The NanoActive™ technology provides nanoformulation solutions for original as well as generic applications in a wide variety of industries including pharmaceuticals, agrochemicals, cosmetics, foods, nutraceu home care.
“The proprietary NanoActive™ technology available top-down milling and high pressure homogenization based technologies. It is a bottom flow nano precipitation method for the synthesis of nanoparticles. The properties of the produced nanoparticles can be modified during the process by the precise control and optimization of various reaction parameters by as much as 90%”
The NanGenex partners acquire a license to the commercialize the NanoActive™ product or product families developed through the collaboration. In 2009, NanGenex expanded its patented including antihypertensives, cholesterol reducers, anti The NanoPharmaActive™ formulations have undergon the parent active molecules.
NanGenex explains that it is in advanced discussions with leading pharmaceutical a partnerships and strategic alliances for the development of novel nano. The drug nanoformulations can increase drug potency and reduce side effects. This brings clinically meaningful benefits to patients.
New Areas of the Brain Become Active After Students Learn PhysicsNews
Parts of the brain not traditionally associated with learning science become active when people are confronted with solving physics problems.READ MORE
Diamonds Could Decrease Cost of Imaging and Spectroscopy DevicesNews
A new approach shows great promise for enhancing the signal from magnetic resonance imaging (MRI) and nuclear magnetic resonance (NMR) using lasers without expensive magnets.
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018